EP300 and colorectal carcinoma: The equivocal results of anti-CRC (and, in general anti-solid tumor) clinical trials involving HDACis 50-52 may be due to HDACi-resistance of these tumors; in the case of CRC, resistance may develop as a result of intra-colonic exposure to butyrate and consequent downregulation of p300-Wnt signaling.